Do stimulants improve functioning in adults with ADHD?. A review of the literature.

European Neuropsychopharmacology

Volumn 23, Issue 6, 2013, Pages 528-533

  Surman, Craig B H ^a   Hammerness, Paul G ^a   Pion, Katie ^a   Faraone, Stephen V ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

ADHD; Attention deficit hyperactivity isorder; Function; Pharmacotherapy; Quality of life; Stimulant

Indexed keywords

AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; FUNCTIONAL STATUS; HUMAN; LEISURE; LIFE; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ENJOYMENT AND SATISFACTION SCALE SHORT FORM; QUALITY OF LIFE INDEX; RATING SCALE; SHEEHAN DISABILITY SCALE; SHORT FORM 36; SOCIAL ADJUSTMENT SCALE; SOCIAL WORK; WELLBEING;

ACTIVITIES OF DAILY LIVING; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; INDIVIDUALIZED MEDICINE; QUALITY OF LIFE;

EID: 84877919585     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.02.010     Document Type: Article

References (36)

1. Adler L.A., Goodman D.W., Kollins S.H., Weisler R.H., Krishnan S., Zhang Y., Biederman J. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 2008, 69:1364-1373.
2. Barkley R., Murphy K., Kwasnik D. Psychological adjustment and adaptive impairments in young adults with ADHD. J. Atten. Disord. 1996, 1:41-54.
3. Barkley R.A., Murphy K.R., Fischer M. ADHD in adults: what the science says 2008, Guilford Press, New York, NY.
4. Biederman J., Faraone S.V., Spencer T., Wilens T., Norman D., Lapey K.A., Mick E., Lehman B.K., Doyle A.E. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 1993, 150:1792-1798.
5. Biederman J. Attention-deficit/hyperactivity disorder: a life span perspective. J. Clin. Psychiatry 1998, 59:4-16.
6. Biederman J., Mick E., Faraone S.V. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am. J. Psychiatry 2000, 157:816-818.
7. Biederman J., Spencer T.J., Wilens T.E., Weisler R.H., Read S.C., Tulloch S.J. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums 2005, 10:16-25.
8. Biederman J., Mick E., Surman C., Doyle R., Hammerness P., Harpold T., Dunkel S., Dougherty M., Aleardi M., Spencer T. A randomized, placebo-controlled trial of OROS-methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 2006, 59:829-835.
9. Biederman J., Petty C.R., Fried R., Kaiser R., Dolan C.R., Schoenfeld S., Doyle A.E., Seidman L.J., Faraone S.V. Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J. Clin. Psychiatry 2008, e1-e6.
10. Buitelaar J.K., Casas M., Philipsen A., Kooij J.J., Ramos-Quiroga J.A., Dejonckheere J., van Oene J.C., Schauble B. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate. Psychol. Med. 2011, 1-10.
11. Endicott J., Nee J., Harrison W., Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol. Bull. 1993, 29:321-326.
12. Faraone S.V., Biederman J., Spencer T., Wilens T., Seidman L.J., Mick E., Doyle A.E. Attention deficit hyperactivity disorder in adults: an overview. Biol. Psychiatry 2000, 48:9-20.
13. Faraone S.V., Spencer T., Aleardi M., Pagano C., Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disorder. J. Clin. Psychopharmacol. 2004, 54:24-29.
14. Faraone S.V., Glatt S.J. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J. Clin. Psychiatry 2010, 71:754-763.
15. Faraone, S.V., Biederman, J., 2004. A controlled study of functional impairments in 500 ADHD adults. In: Proceedings of the 157th Annual Meeting of the American Psychiatric Association. May 1-6, APA, New York, NY, p. 114.
16. Fayyad J., De Graaf R., Kessler R., Alonso J., Angermeyer M., Demyttenaere K., De Girolamo G., Haro J.M., Karam E.G., Lara C., Lepine J.P., Ormel J., Posada-Villa J., Zaslavsky A.M., Jin R. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br. J. Psychiatry 2007, 190:402-409.
17. Gibbins C., Weiss M. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr. Psychiatry Rep. 2007, 9:420-426.
18. Goodman D.W., Ginsberg L., Weisler R.H., Cutler A.J., Hodgkins P. An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums 2005, 10:26-34.
19. Gordon M., Antshel K., Faraone S., Barkley R., Lewandowski L., Hudziak J.J., Biederman J., Cunningham C. Symptoms versus impairment: the case for respecting DSM-IV's criterion D. J. Atten. Disord. 2006, 9:465-475.
20. Kessler R.C., Adler L., Ames M., Barkley R.A., Birnbaum H., Greenberg P., Johnston J.A., Spencer T., Ustun T.B. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J. Occup. Environ. Med. 2005, 47:565-572.
21. Kessler R.C., Adler L., Barkley R., Biederman J., Conners C.K., Demler O., Faraone S.V., Greenhill L.L., Howes M.J., Secnik K., Spencer T., Ustun T.B., Walters E.E., Zaslavsky A.M. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am. J. Psychiatry 2006, 163:716-723.
22. Landgraf J.M. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J. Atten. Disord. 2007, 11:351-362.
23. McHorney C.A., Ware J.E., Lu J.F., Sherbourne C.D. The MOS 36-item Short-Form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med. Care 1994, 32:40-66.
24. Mick E., Spencer T., Faraone S.V., Biederman J., Zhang H.F. Assessing the validity of the quality of life enjoyment and satisfaction questionnaire short form in adults with ADHD. J. Atten. Disord 2007.
25. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 2007, 164:942-948.
26. Rosler M., Ginsberg Y., Arngrim T., Adamou M., Niemela A., Dejonkheere J., van Oene J., Schauble B. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate. World J. Biol. Psychiatry 2011.
27. Safren S.A., Otto M.W., Sprich S., Winett C.L., Wilens T.E., Biederman J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav. Res. Ther. 2005, 43:831-842.
28. Sheehan D.V., Harnett-Sheehan K., Raj B.A. The measurement of disability. Int. Clin. Psychopharmacol. 1996, 11(Suppl. 3):89-95.
29. Spencer T., Biederman J., Wilens T., Faraone S., Prince J., Gerard K., Doyle R., Parekh A., Kagan J., Bearman S.K. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 2001, 58:775-782.
30. Spencer T.J., Adler L.A., McGough J.J., Muniz R., Jiang H., Pestreich L. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 2007, 61:1380-1387.
31. Spencer T.J., Landgraf J.M., Adler L.A., Weisler R.H., Anderson C.S., Youcha S.H. Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2008, 69:1766-1775.
32. Surman C.B., Monuteaux M.C., Petty C.R., Faraone S.V., Spencer T.J., Chu N.F., Biederman J. Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study. J. Clin. Psychiatry 2010, 71:1612-1616.
33. Weiss G., Hechtman L. Hyperactive children grown up, in ADHD in children, adolescents, and adults 1993, Guilford Press, New York, NY.
34. Weiss M.D., Gibbins C., Goodman D.W., Hodgkins P.S., Landgraf J.M., Faraone S.V. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 2010, 71:381-390.
35. Weissman M.M., Bothwell S. Assessment of social adjustment by patient self-report. Arch. Gen. Psychiatry 1976, 33:1111-1115.
36. Wender P.H., Reimherr F.W., Marchant B.K., Sanford M.E., Czajkowski L.A., Tomb D.A. A one year trial of methylphenidate in the treatment of ADHD. J. Atten. Disord. 2011, 15:36-45.